Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Casdozokitug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Casdozokitug overview

Casdozokitug (SRF-388) is under development for the treatment of solid tumors including renal cell cancer, non-small-cell lung cancer, squamous cell non-small-cell lung carcinoma, hepatocellular cancer and metastatic hepatocellular cancer. It is a monoclonal antibody acts by targeting cytokine IL-27. It is administered through intravenous route.

It was also under development for the treatment of lung cancer.

Coherus BioSciences overview

Coherus BioSciences (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats Nasopharyngeal Carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for Hepatocellular Carcinoma and Non-Small Cell Lung Cancer; CHS-114 and CHS-1000, which targets Solid Tumors. The company also develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor and YUSIMRY, a biosimilar to Humiram which treats inflammatory diseasesCoherus is headquartered in Redwood City, California, the US.

For a complete picture of Casdozokitug’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.